Sign In
Buy PCRX
$22.25
-0.710 (-3.09%)
At Close: Jun 02, 2026
Pacira to Report 2025 Financial Results on Thursday February 26, 2026
04:01pm, Thursday, 12'th Feb 2026
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices
08:00am, Thursday, 12'th Feb 2026
BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted n
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Monday, 09'th Feb 2026
BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pati
Pacira BioSciences: Mispriced On Generic Risks That Are Years Away
06:31am, Monday, 09'th Feb 2026
Pacira BioSciences trades at distressed levels due to fears of EXPAREL patent erosion, despite strong cash flow and 78% gross margins. EXPAREL's manufacturing complexity and hospital adoption create a
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
11:02am, Tuesday, 03'rd Feb 2026
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Recommendation of “Hold” by Analysts
01:28am, Thursday, 29'th Jan 2026
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) have been given a consensus rating of "Hold" by the six analysts that are currently covering the company, MarketBeat reports. One in
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors
08:00am, Wednesday, 28'th Jan 2026
-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the indust
Hussman Strategic Advisors Inc. Makes New Investment in Pacira BioSciences, Inc. $PCRX
05:52am, Wednesday, 28'th Jan 2026
Hussman Strategic Advisors Inc. purchased a new stake in Pacira BioSciences, Inc. (NASDAQ: PCRX) during the undefined quarter, according to the company in its most recent Form 13F filing with the Secu
Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:06pm, Wednesday, 14'th Jan 2026
Pacira BioSciences, Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific
11:20am, Wednesday, 14'th Jan 2026
Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific, unlocking royalties and new revenue channels to support international growth.
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets
08:00am, Tuesday, 13'th Jan 2026
-- LG Chem becomes exclusive distributor of EXPAREL -- – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy–
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
11:17am, Monday, 12'th Jan 2026
Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Down – Time to Sell?
03:26am, Sunday, 11'th Jan 2026
Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX - Get Free Report) gapped down before the market opened on Friday. The stock had previously closed at $26.02, but opened at $24.64. Pacira BioSciences
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues
04:01pm, Thursday, 08'th Jan 2026
-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences,
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences
08:00am, Wednesday, 07'th Jan 2026
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the liv
